CGC dividend history
Canopy Growth Corporation (CGC) dividend declarations and ex-dividend dates - real-time wire coverage of every payout disclosure.
Recent dividend items
- CANOPY GROWTH ANNOUNCES RESULTS OF SPECIAL MEETING OF SHAREHOLDERSShareholders overwhelmingly approve the creation of a new class of Exchangeable Shares of Canopy Growth, enabling the acceleration of Canopy Growth's entry into the U.S. THC market, which is expected to be approximately $50B in 2026.1Canopy USA expected to advance imminently with triggering acquisition of U.S. assets.SMITHS FALLS, ON, April 15, 2024 /PRNewswire/ - Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX:WEED) (NASDAQ:CGC) today announced the voting results from its special meeting of shareholders held on Friday, April 12, 2024 (the "Meeting"). A total
- Rivers Obtains Court Approval of the Arrangement with Canopy GrowthTORONTO, Feb. 18, 2021 /PRNewswire/ - Canopy Rivers Inc. ("Rivers" or the "Company") today announced that the Ontario Superior Court of Justice (Commercial List) has approved the previously announced plan of arrangement (the "Arrangement") involving Canopy Growth Corporation ("Canopy Growth") (TSX: WEED) (NASDAQ: CGC), pursuant to which Rivers will transfer three portfolio assets to Canopy Growth in exchange for approximately $115 million in cash, approximately 3.65 million common shares of Canopy Growth, and the cancellation of all multiple voting shares and subordinate voting shares of Rivers held by Canopy Growth. Completion of the Arrangement remains subject to the satisfaction or waiver
- RIV Capital Closes Plan of Arrangement Involving Canopy Growth, Paving Way for Entry Into U.S. MarketTORONTO, Feb. 23, 2021 /PRNewswire/ - RIV Capital Inc. (formerly Canopy Rivers Inc.) ("RIV Capital" or the "Company") (TSX: RIV) (OTC: CNPOF) is pleased to announce the completion of the previously announced plan of arrangement (the "Arrangement") involving Canopy Growth Corporation ("Canopy Growth") (TSX: WEED) (NASDAQ: CGC). Pursuant to the Arrangement, RIV Capital, through its wholly-owned subsidiary, RIV Capital Corporation (formerly Canopy Rivers Corporation) ("RCC"), transferred its interests in TerrAscend Corp. ("TerrAscend"), TerrAscend Canada Inc. ("TerrAscend Canada"), Les Serres Vert Cannabis Inc. ("Vert Mirabel") (other than the shares transferred to Serres Bertrand as describe
- Rivers Shareholders Approve Plan of Arrangement with Canopy GrowthTORONTO, Feb. 16, 2021 /PRNewswire/ - Canopy Rivers Inc. ("Rivers" or the "Company") (TSX: RIV) (OTC: CNPOF) is pleased to announce that its shareholders voted today to approve the previously announced plan of arrangement (the "Arrangement") involving Canopy Growth Corporation ("Canopy Growth") (TSX: WEED) (NASDAQ: CGC). Approximately 99.87% of the votes cast by Rivers' shareholders were voted in favour of the Arrangement, including approximately 99.85% of the votes cast by Rivers' shareholders other than Canopy Growth, whose votes were required to be excluded pursuant to Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions. Approval was requi
- Canopy Rivers Reports Third Quarter Fiscal Year 2021 Financial ResultsComprehensive income of $82.2 million driven by significant increase in value of investment in TerrAscend Announced transformative and accretive transaction with Canopy Growth, expected to close by the end of February Anticipates being in strong financial and strategic position to pivot to the U.S. market following the closing of CGC Transaction TORONTO, Feb. 10, 2021 /PRNewswire/ - Canopy Rivers Inc. ("Canopy Rivers" or the "Company") (TSX: RIV) (OTC: CNPOF) today released its unaudited condensed interim consolidated financial statements and management's discussion and analysis ("MD&A") for the three and nine months ended December 31, 2020 ("Q3 2021"). "Our quarter was highlighted by t
- How An Ancient Medicine Is Taking On The $16 Trillion Pharmaceutical IndustryLONDON, Dec. 3, 2020 /PRNewswire/ -- 2021 could be a big year for this soon-to-be $16-trillion biotech opportunity. More importantly, it could be a big year for companies pioneering a new form of therapy that could effectively treat the world's #1 disability. It's a disability that's costing the economy $1 trillion in lost production every single year. In fact, the revolutionary treatment could be at our doorstep by 2021. And the next few months are critical. Mentioned in today's commentary includes: Constellation Brands, Inc. (NYSE: STZ), Molson Coors Beverage Company (NYSE: TAP), Altria Group, Inc. (NYSE: MO), GW Pharmaceuticals plc (NASDAQ: GWPH), Curaleaf Holdings, Inc. (OTCQX: CUR